BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment In Vivo BTK inhibitor 10 (oral gavage; 30 mg/kg; 21 days; once daily) has a significant improvement in arthritis symptoms in CIA mice. The damage of each of the 4 paws in mice is divided into 0-4 to calculate the total score of the limbs. After 21 days’ oral treatment, BTK030 reduces the arthritic score to 3.62 while the control group shows a value of 8.33 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: DBA/1J mice injected with collagen as a CIA model Dosage: 30 mg/kg Administration: oral gavage; 21 days; once daily Result: Decreased arthritis scores significantly when it compares to control group. Form:Solid IC50& Target:IC50: Bruton kinase (BTK)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
BTK inhibitor 10
CAS number：2241732-30-7 molecular formula：C25H23N5O3
overview
compound introduction
Specs
| Chinese alias | BTK抑制剂10 | ||
| English alias | - | ||
| CAS number | 2241732-30-7 | molecular formula | C25H23N5O3 |
| molecular weight | 441.48 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
